Business Wire

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA ® Is Now Effective

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...
Seeking Alpha

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
Nasdaq

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...
Benzinga.com

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio, Inc. (NASDAQ:IBRX) on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ...
Business Wire

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Los Angeles Business Journal

FDA Delivers Blow to ImmunityBio

The Food and Drug Administration delivers a setback to ImmunityBio’s desire to expand usage of its primary drug, while Atara Biotherapeutics gets the go-ahead for its clinical trials for another.
Benzinga.com

What's Going On With ImmunityBio Shares Tuesday?

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
Los Angeles Business Journal

ImmunityBio, Xencor Drugs Win E.U. Nods

Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver City-based ImmunityBio Inc. announced that the European Medicines Agency, ...
Morningstar

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending ...
FierceBiotech

ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial

ImmunityBio has reported ongoing complete responses of up to 15 months in two recipients of its CAR-NK cell therapy, leading the biopharma to talk up the prospects of the off-the-shelf blood cancer ...
ETF Daily News

ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $30.00 price ...